Anzeige
Mehr »
Mittwoch, 29.04.2026 - Börsentäglich über 12.000 News
250 Tage bis zum Pentagon-Magnetverbot: Wie ein 46-Mio.-CAD-Small-Cap profitieren könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
176 Leser
Artikel bewerten:
(1)

INTCO Medical Reports 2025 Results with Resilient Growth, Revenue Reaches Four-Year High as Industry Rebalances

ZIBO, China, April 29, 2026 /PRNewswire/ -- INTCO Medical ("INTCO" or "the Company"), a leading global manufacturer of disposable gloves, reported its 2025 annual results, with revenue reaching RMB 9.93 billion (approximately US$1.46 billion), up 4.23% year over year and marking a four-year high.

The company's annualized production capacity for disposable non-latex gloves reached 103 billion pieces, including 70 billion nitrile gloves, placing INTCO among the world's largest disposable glove manufacturers by production capacity and a top global nitrile glove manufacturer.

Continue Reading

During the reporting period, INTCO maintained stable operations amid industry rebalancing. Net profit attributable to shareholders reached RMB 1.01 billion (approximately US$148.03 million), while total assets exceeded RMB 40 billion (approximately US$5.86 billion), up 15.77% year over year. Gross margin rose 0.48 percentage points to 24.12%, and net cash flow from operating activities increased 74.69% to RMB 1.89 billion (approximately US$277.00 million), supporting the company's global expansion and long-term growth.

Scale and Manufacturing Capabilities Strengthen Core Business

Disposable gloves remained INTCO Medical's core business. As of the end of 2025, the company operated 10 R&D and manufacturing bases worldwide, with annualized capacity for disposable non-latex gloves reaching 103 billion pieces, including 70 billion nitrile gloves and 33 billion vinyl gloves.

The company continued to enhance its automated production systems, self-developed production lines and precision DCS systems to improve production efficiency, energy utilization and product quality. Its production scale remained among the industry's largest, with product yield continuing to stay above 99%.

With a global development strategy, INTCO Medical expanded overseas production capacity, including new facilities in Vietnam, strengthening supply chain resilience, supporting stable delivery and enhancing responsiveness to regional demand.

Beyond its core glove business, INTCO expanded its healthcare and personal protection portfolio, with rehabilitation medical equipment and physical therapy businesses growing and supporting a more balanced revenue mix.

Global Reach, Innovation and Digitalization Support Long-Term Growth

Investment in innovation remained a key strategic priority. In 2025, research and development spending reached RMB 404 million (approximately US$59.21 million), representing 4.07% of revenue and significantly above the industry average, reflecting the company's continued commitment to innovation.

The company continued to advance new materials, automation technologies, and product development, including the launch of innovative products such as Syntex Synthetic Disposable Latex Gloves and Synmax Pro Exam Gloves. Total patent holdings continued to grow, strengthening long-term competitive barriers.

INTCO continued to deepen its global market network, serving more than 15,000 customers across more than 150 countries and regions. Supported by a global marketing team of nearly 500 professionals, the company has established marketing and service centers in the U.S., Canada, Germany, Japan, Malaysia, Singapore and Hong Kong SAR, China, with plans to further expand in the Middle East, South America and Oceania to better support local customers.

INTCO is integrating digital technologies and AI across its operations, using data platforms and AI-driven tools to improve efficiency, decision-making and internal capabilities. The company continued to advance its ESG practices, including wind and solar projects that generated 12,537.23 MWh of clean energy in 2025, supporting sustainable development.

Looking ahead, INTCO will leverage its scale, technology and global network to strengthen its healthcare supply chain, improve efficiency, expand overseas capacity and accelerate product innovation.

About INTCO Medical

INTCO Medical is a leading global manufacturer of disposable gloves. As a high-tech manufacturing company, INTCO specializes in the R&D, production and marketing of medical consumables and durable medical equipment. The company's core business segments include medical consumables, rehabilitation medical equipment and physical therapy. For more information, please visit https://www.intcomedical.com/.

SOURCE INTCO MEDICAL

© 2026 PR Newswire
Vergessen Sie Gold, Silber und Öl: Nächste Megarallye startet!
Die Märkte feiern neue Rekorde – doch im Hintergrund braut sich eine Entwicklung zusammen, die alles verändern könnte. Die anhaltende Sperrung der Straße von Hormus sorgt laut IEA für eine der größten Energiekrisen aller Zeiten. Gleichzeitig schießen die Preise für Düngemittel und Agrarrohstoffe bereits nach oben.

Damit droht ein perfekter Sturm: steigende Energiepreise, explodierende Produktionskosten und ein möglicher Super-El-Nino, der weltweit Ernten gefährdet. Erste Auswirkungen sind längst sichtbar – Weizen, Soja und Kakao verteuern sich deutlich, während Lebensmittelpreise vor dem nächsten Sprung stehen könnten.

Für Anleger bedeutet das nicht nur Risiken, sondern enorme Chancen. Denn während klassische Märkte unter Druck geraten könnten, entsteht auf den Feldern und Plantagen der nächste große Rohstoffzyklus. Wer sich jetzt richtig positioniert, kann von einer Entwicklung profitieren, die weit über Öl und Metalle hinausgeht.

In unserem aktuellen Spezialreport stellen wir drei Aktien vor, die besonders aussichtsreich sind, um von diesem Trend zu profitieren – solide positioniert, strategisch relevant und mit erheblichem Aufwärtspotenzial.



Jetzt den kostenlosen Report sichern – bevor der Agrar-Boom voll durchschlägt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.